Business
Final Results
Final Results.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n\n \n \n \n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation.\n \n 10 April 2025\nProteome Sciences plc\n(\"Proteome Sciences\" the \"Company\" or the \"Group\")\n \nFinal results for the year ended 31 December 2024\n \nThe Company is pleased to announce its audited results for the year ended 31 December 2024.\nHighlights:\n· Total revenues of £4.89m (2023: £5.03m)\n· TMT® reagent sales, and royalties of £4.01m (2023: £3.40m)\n· Proteomic services revenues of £0.87m (2023: £1.63m)\n· Gross profit £0.67m (2023: £1.65m)\n· Loss after tax £3.41m (2023: £2.44)\n· Cash at year end £1.13m (2023: £2.03m)\n· Cost of sale and administrative costs £7.24m (2023: £6.65m)\n· Adjusted EBITDA* loss of £1.48m (2023: loss of £0.92m)\n* EBITDA is a non-GAAP company specific measure which is considered to be a key performance indicator of the Group's financial performance. Adjusted EBITDA is calculated as operating profit before depreciation (including right-to-use assets amortisation), amortisation, non-recurring costs, and employee share-based payment.\n \nExecutive Chairman of Proteome Sciences plc, commented:\n \nThe back end of 2024 showed a good recovery from the impact of the global downturn in the biotech and pharma markets over the previous year. Following the considerable increase in customer orders and services in the second half of 2024 we are pleased to reiterate that the momentum from the second half of last year has continued into 2025 with the pipeline now extending well into 2026.\n \nWe are optimistic that our proteomics business has gone through a significant inflection point and that it can deliver substantial increases and returns in the future.\n \nReport and Accounts and Notice of Annual General Meeting:\nCopies of the Annual Report a...